en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


1/2012
vol. 50
 
Share:
Share:
abstract:
Review paper

The role of anticentromere antibodies in diagnosis of rheumatic and cancer diseases

Joanna Pyka
,
Iwona Horbacz
,
Elwira Biernacka
,
Jakub Ząbek

Reumatologia 2012; 50, 1: 52–56
Online publish date: 2012/03/02
View full text Get citation
 
Autoantibodies to centromere proteins (CENPs) were first described in 1980 in limited cutaneous SSc (lcSSc) patients. Since that time a number of CENPs have been identified as autoantibody targets in many rheumatic and cancer diseases (Table I, Fig. 1). The general method for detection of anti-centromere antibodies (ACA) is indirect immunofluorescence using HEp-2 cell slides. Autoantibodies CENP-A, -B, -C are relatively specific biomarkers for lcSSc (CREST syndrome). This review focuses on updating information on CENP antibodies against particular autoantigens and their new clinical associations: anti-CENP-A with early Ssc, anti-CENP-D IgM with SLE + Sjögren syndrome, anti-CENP-H (in SSA/SSB negative patients) and anti-CENP-C with Sjögren syndrome. Anti-CENP-F antibodies have totally different clinical significance and occur mainly in cancer diseases.
keywords:

anti-centromere antibodies, centromere proteins, cell division cycle




Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.